Pharmaceutical

Okomera to Present Automated Desktop Organoid Screening Instrument for Oncology Drug Discovery at SLAS 2025 in San Diego

PARIS, Jan. 28, 2025 /PRNewswire/ -- Okomera is a biotech startup developing cutting-edge solutions for oncology drug discovery and will…

11 months ago

Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights

BASEL, Switzerland, Jan. 28, 2025 /PRNewswire/ -- Lyfegen, a global innovator in drug market access, pricing, and rebate management, has announced…

11 months ago

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset,…

11 months ago

Corsair Pharma Partners with InstantGMP® to Ensure Quality for Clinical Trials

CARY, N.C., Jan. 28, 2025 /PRNewswire/ -- InstantGMP™, a leader in fully integrated GMP-compliant software solutions for pharmaceutical manufacturing, proudly…

11 months ago

Sharps Technology, Inc. Announces Pricing of Upsized $20.0 Million Underwritten Public Offering

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and…

11 months ago

Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical…

11 months ago

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial…

11 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to…

11 months ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with…

11 months ago

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global…

11 months ago